Table A3;
Maximum values for the marginal annual FOI by study site, previous infection status and use of AL, and by age group
| Site | Previous infection status and use of AL | Maximum annual FOI | ||
|---|---|---|---|---|
| <1 year | 1–4 years | 5–10 years | ||
| Nagongera | Negative, no AL | 3·99 | 4·21 | 8·49 |
| Negative, AL | 4·45 | 4·80 | 9·69 | |
| Symptomatic | 2·21 | 2·07 | 4·14 | |
| Asymptomatic | 7·73 | 9·21 | 18·70 | |
| Kihihi | Negative, no AL | 5·35 | 24·95 | 64·82 |
| Negative, AL | 1·46 | 4·64 | 11·78 | |
| Symptomatic | 1·06 | 3·23 | 8·11 | |
| Asymptomatic | 4·62 | 20·25 | 52·56 | |
| Walukuba | Negative, no AL | 18·01 | 6·65 | 11·28 |
| Negative, AL | 20·07 | 7·41 | 12·58 | |
| Symptomatic | 8·02 | 2·95 | 5·01 | |
| Asymptomatic | 98·24 | 36·34 | 61·66 | |